Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × rrCLL × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2028 Neoplasms 1450 Carcinoma, Non-Small-Cell Lung 1345 Prostatic Neoplasms 1082 Multiple Myeloma 857 Leukemia, Myeloid, Acute 757 Colorectal Neoplasms 701 Neoplasm Metastasis 696 Lung Neoplasms 688 Melanoma 679 Lymphoma 659 Leukemia 592 Lymphoma, Non-Hodgkin 588 Leukemia, Lymphocytic, Chronic, B-Cell 534 Ovarian Neoplasms 527 Pancreatic Neoplasms 492 Precursor Cell Lymphoblastic Leukemia-Lymphoma 480 Recurrence 471 Myelodysplastic Syndromes 419 Lymphoma, Follicular 415 Carcinoma, Renal Cell 408 Head and Neck Neoplasms 400 Glioblastoma 377 Lymphoma, Large B-Cell, Diffuse 375 Brain Neoplasms 372 Hodgkin Disease 350 Carcinoma, Hepatocellular 330 Squamous Cell Carcinoma of Head and Neck 319 Lymphoma, Mantle-Cell 305 Sarcoma 282

Interventions

pembrolizumab 1 dinaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02684617 2021-03-01

KEYNOTE-155

Merck Sharp & Dohme LLC

Phase 1 Terminated

75 enrolled 17 charts

rrCLL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡